Prevention of Hepatitis B Recurrence in Liver Transplant Patients Using Oral Antiviral Therapy without Long-Term Hepatitis B Immunoglobulin

被引:16
作者
Ahn, Joseph [1 ]
Cohen, Stanley Martin [1 ]
机构
[1] Loyola Univ, Med Ctr, Dept Hepatol, Maywood, IL 60153 USA
关键词
Hepatitis B; Liver transplantation; Immunoglobulin; LAMIVUDINE PLUS HBIG; IMMUNE GLOBULIN; ADEFOVIR DIPIVOXIL; VIRUS RECURRENCE; COMPARING LAMIVUDINE; PROPHYLAXIS; RECIPIENTS; MONOTHERAPY; MANAGEMENT; EFFICACY;
D O I
10.5812/kowsar.1735143X.717
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Small studies have suggested that nucleos(t)ide analogue therapy (NAT) with reduced hepatitis B immunoglobulin (HBIG) duration may be efficacious in preventing post-liver transplantation (LT) HBV recurrence. Objectives: This larger study evaluates the use of NAT with short term (< 6 mo) or no HBIG for prevention of post-LT HBV recurrence. Patients and Methods: All HBV patients undergoing LT at a university transplant center between 2002 and 2007 were identified retrospectively. Patient demographics, medication regimen, and adverse events were noted. The primary endpoint was HBV recurrence and secondary endpoints were graft and patient survival. Results: 28 study patients were identified. Of these 28 patients, 4 (14%) received no HBIG, 6 (22%) received only inpatient HBIG, and 18 (64%) received inpatient HBIG and outpatient HBIG. 16 of the 28 patients (57%) received combination NAT and 12 patients (43%) received single NAT. At a median time of 15.5 months (range 9-24 months) post-LT, 4 of the 28 patients (14%) had recurrent HBV. Of those patients with recurrent HBV, 3 received both inpatient and outpatient HBIG and 1 received no HBIG. All cases of HBV recurrence were associated with noncompliance. Conclusions: NAT with short-term or no HBIG was efficacious and safe in preventing post-LT HBV. All compliant patients were HBV-free, including 9 patients who received no HBIG or only inpatient HBIG. Additional studies using NAT without HBIG appear justified. (C) 2011 Kowsar M.P.Co. All rights reserved.
引用
收藏
页码:638 / 645
页数:8
相关论文
共 24 条
[11]   Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants [J].
Marzano, A ;
Lampertico, P ;
Mazzaferro, V ;
Carenzi, S ;
Vigano, M ;
Romito, R ;
Pulvirenti, A ;
Franchello, A ;
Colombo, M ;
Salizzoni, M ;
Rizzetto, M .
LIVER TRANSPLANTATION, 2005, 11 (05) :532-538
[12]  
McGory R, 2000, CLIN TRANSPLANT, V14, P29
[13]   High pre-treatment serum hepatitis B virus titre predicts failure of lamivudine prophylaxis and graft re-infection after liver transplantation [J].
Mutimer, D ;
Pillay, D ;
Dragon, E ;
Tang, H ;
Ahmed, M ;
O'Donnell, K ;
Shaw, J ;
Burroughs, R ;
Rand, D ;
Cane, P ;
Martin, B ;
Buchan, S ;
Boxall, E ;
Barmat, S ;
Gutekunst, K ;
McMaster, P ;
Elias, E .
JOURNAL OF HEPATOLOGY, 1999, 30 (04) :715-721
[14]   Hepatitis B prophylaxis post-liver transplant without maintenance hepatitis B immunoglobulin therapy [J].
Nath, DS ;
Kalis, A ;
Nelson, S ;
Payne, WD ;
Lake, JR ;
Humar, A .
CLINICAL TRANSPLANTATION, 2006, 20 (02) :206-210
[15]   Combination therapy in liver transplant recipients with hepatitis B virus without hepatitis B immune globulin [J].
Neff, Guy W. ;
Kemmer, Nyingi ;
Kaiser, Tiffany E. .
DIGESTIVE DISEASES AND SCIENCES, 2007, 52 (10) :2497-2500
[16]   A multicenter United States-Canadian trial to assess lamivudine monotherapy before and after liver transplantation for chronic hepatitis [J].
Perrillo, RP ;
Wright, T ;
Rakela, J ;
Levy, G ;
Schiff, E ;
Gish, R ;
Martin, P ;
Dienstag, J ;
Adams, P ;
Dickson, R ;
Anschuetz, G ;
Bell, S ;
Condreay, L ;
Brown, N .
HEPATOLOGY, 2001, 33 (02) :424-432
[17]   HBV DNA persistence 10 years after liver transplantation despite successful anti-HBS passive immunoprophylaxis [J].
Roche, B ;
Feray, C ;
Gigou, M ;
Roque-Afonso, AM ;
Arulnaden, JL ;
Delvart, V ;
Dussaix, E ;
Guettier, C ;
Bismuth, H ;
Samuel, D .
HEPATOLOGY, 2003, 38 (01) :86-95
[18]   LIVER-TRANSPLANTATION IN EUROPEAN PATIENTS WITH THE HEPATITIS-B SURFACE-ANTIGEN [J].
SAMUEL, D ;
MULLER, R ;
ALEXANDER, G ;
FASSATI, L ;
DUCOT, B ;
BENHAMOU, JP ;
BISMUTH, H .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 329 (25) :1842-1847
[19]   Adefovir dipivoxil for wait-listed and post-liver transplantation patients with lamivudine-resistant hepatitis B: Final long-term results [J].
Schiff, Eugene ;
Lai, Ching-Lung ;
Hadziyannis, Stephanos ;
Neuhaus, Peter ;
Terrault, Norah ;
Colombo, Massimo ;
Tillmann, Hans ;
Samuel, Didier ;
Zeuzem, Stefan ;
Villeneuve, Jean-Pierre ;
Arterburn, Sarah ;
Borroto-Esoda, Katyna ;
Brosgart, Carol ;
Chuck, Steven ;
Shakil, Ahmad Obaid ;
Fung, John ;
Alberti, Alfredo ;
Lok, Anna ;
Picciotto, Antonio ;
Torre, Francesco ;
Riely, Caroline ;
Trepo, Christian ;
Bizollon, Thierry ;
Botta-Fridlund, Danielle ;
Gerolami, Rene ;
Douglas, David ;
Ranjan, Dinesh ;
Faust, Dominik ;
Trojan, Joerg ;
Gane, Edward ;
Villa, Erica ;
Boarino, Valentina ;
Sokal, Etienne ;
Starkel, Peter ;
Bonino, Ferruccio ;
Brunetto, Maurizia ;
Gordon, Fred ;
Pratt, JoAnne ;
Berr, Frieder ;
Schiefke, Ingolf ;
McCaughan, Geoff ;
Strasser, Simone ;
Dusheiko, Geoffrey ;
Pageaux, Georges Philipp ;
Larrey, Dominique ;
Pastore, Giuseppe ;
Santantonio, Teresa ;
Alexander, Graeme ;
Woodall, Tracy ;
Van Vlierberghe, Hans .
LIVER TRANSPLANTATION, 2007, 13 (03) :349-360
[20]   Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation [J].
Takaki, Akinobu ;
Yagi, Takahito ;
Iwasaki, Yoshiaki ;
Sadamori, Hiroshi ;
Matsukawa, Hiroyoshi ;
Matsuda, Hiroaki ;
Shinoura, Susumu ;
Umeda, Yuuzou ;
Miyake, Yasuhiro ;
Terada, Ryou ;
Kobashi, Haruhiko ;
Sakaguchi, Kohsaku ;
Tanaka, Noriaki ;
Shiratori, Yasushi .
TRANSPLANTATION, 2007, 83 (02) :231-233